Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 7, 2023Statistics in Biopharmaceutical Research

DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZiji YuTakeda (United States)YWYanzhao WangWorcester Polytechnic InstituteJLJianchang LinTakeda (Japan)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yu et al. (2023) studied this question.

synapsesocial.com/papers/6a1bc135d54006be995ee567https://doi.org/10.1080/19466315.2023.2292816
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Drug-Dosing Conundrum in Oncology — When Less Is More2021 · 295 citations
  2. 2A History of Cancer Chemotherapy2008 · 1,988 citations
  3. 3Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?2009 · 101 citations
  4. 4A flexible design for multiple armed screening trials2001 · 85 citations